Standard BioTools to Merge with Treeline; SomaScan Divestment Complete
Standard BioTools Inc. announced a definitive merger agreement with Treeline Biosciences, Inc., an all-stock transaction expected to close in the second half of 2026, with existing shareholders holding approximately 16% of the combined entity. This follows the completed divestment of its SomaScan Business to Illumina, Inc. on January 30, 2026, which generated $388.2 million in net cash and a pre-tax gain of $172.3 million. The company reported a net income of $100.3 million for the six months ended June 30, 2026, primarily driven by the divestment, and significantly increased its cash position.
Key Highlights
- Merger agreement with Treeline Biosciences, Inc. announced on June 6, 2026.
- Existing shareholders expected to hold approximately 16% of the combined company.
- Divestment of SomaScan Business to Illumina completed on January 30, 2026.
- Received $388.2 million net cash consideration from SomaScan divestment.
- Recognized a pre-tax gain of $172.3 million on the sale of the SomaScan Business.
- Net income for the six months ended June 30, 2026, was $100.3 million.
- Cash and cash equivalents increased to $270.0 million as of June 30, 2026.
- Total current liabilities decreased to $56.8 million as of June 30, 2026.
Price Impact
More from LAB
Standard BioTools Q2 Revenue $20.1M; Adjusted EBITDA -$2.5M; Treeline Merger On Track
Standard BioTools Q2 Revenue $20.1M; Adj. EBITDA Improves 84%
Standard BioTools Sells Mass Cytometry Business; Gets $30M Illumina Buyout